CannTrust Holdings Inc. Stock descends a lot in 2019

CannTrust Holdings Inc. is a leading federally licensed provider of medical cannabis. It is the winner of 7 Canadian Cannabis Awards in 2018, including the top award, Licensed Producer of the Year. The company connects patients to quality products, educational resources and personalized service. The company is backed by more than 40 years of pharmaceutical and healthcare expertise.

The company does research, innovation and contributes to the growing body of evidence-based research regarding the use and efficacy of cannabis. The company's exclusive pharma partner is Apotex. The company has a compassionate use program to support patients with financial needs.

CannTrust Holdings Inc. has a growing facility that is a 430,000 square foot greenhouse in the Niagara region. In the Canadian Cannabis industry, the facility is the first of its kind to be designed and engineered using advanced perpetual growing technology. The facility is one of the largest in North America. Phase 1 is completed. Phase 2 is coming on-line in 2019. The company continues to expand to ensure that it has a continuous supply of quality products and quality customer service.

CannTrust Holdings Inc. is listed on the TSE as TRST. The cannabis company's stock has lost about 90% of its value this year. For this year, the company had a high of $13.48 in March 2019. The company is based in Vaughan, Ontario, Canada.

CannTrust has to provide more financial statements by March 2020. This was the deadline set by TSX. If the company doesn't provide those certain financial statements, the Company's securities will be delisted 30 days after the deadline. CannTrust is preparing to successfully meet the TSX deadline. Certain issues within the company now require additional accounting work.

This looks like a tough battle for CannTrust Stock. Also, the market is faced with a large oversupply of product. The retail capabilities for the product are limited.